New and Investigational ART Drugs and Strategies



Judith S. Currier, MD, MSc Division of Infectious Diseases David Geffen School of Medicine University of California Los Angeles

2021 Ryan W

Financial Relationships With Ineligible Companies (Formerly Described as Commercial Interests by the ACCME) Within the Last 2 Years

Dr Currier has no relevant financial relationships with ineligible companies to disclose. (Updated 9/20/21)

Learning Objectives


At the end of this presentations, learners will be able to:

- List 2 investigational drugs currently in phase III trials
- Describe how these investigational agents might be used in treatment in the future

New Drugs on the Horizon

Islatravir Lenacapravir GSK 3640254 (aka GSK "254) Investigational Aspects of Recently approved Agents Long acting Cabotegravir and Rilpivirine






Islatravir: Safety Data Laboratory (P011 Study)

participants in any group, n/N (%)	ISL 0.25 mg + DOR QD	ISL 0.75 mg + DOR QD	ISL 2.25 mg + DOR QD	DOR/ 3TC/ TDF QD
Fasting triglycerides (mg/dL) Grade 3: > 500-1000	2/29 (6.9)	0/30 (0)	1/29 (3.4)	0/26 (0)
Alanine aminotransferase (IU/ L) • Grade 3: 5.0 to < 10.0 x ULN	0/29 (0)	1/30 (3.3)	2/31 (6.5)	1/31 (3.2)
Creatinine kinase (IU/L) • Grade 3: 10.0 to < 20.0 x ULN • Grade 4: <u>></u> 20.0 x ULN	4/29 (13.8) 1/29 (3.4)	0/30 (0) 2/30 (6.7)	0/31 (0) 3/31 (9.7)	1/31 (3.2) 1/31 (3.2)

	ISL (0.25 mg) + DOR QD	ISL (0.75 mg) + DOR QD	ISL (2.25 mg) + DOR QD		DOR/ 3TC/ TDF QD	
	N=29	N=30	N=31	N=90	N=31	
Outcome (FDA Snaps	hot Approach)					
HIV-1 RNA < 50 copies/ mL, n (%)	25 (86.2)	27(90.0)	21(67.7)	73(81.1)	25(80.6)	
HIV-1 RNA ≥ 50 copies/ mL, n (%)		2 (6.7)		9 (10.0)	2 (6.5)	
No virologic data at Week 96 window , n (%)						
Reasons for no virologic data in window						
Discontinued due to death or Ae ^a , n (%)	0	0	2 (6.5)	2 (2.2)	1 (3.2)	
Discontinued for other reasons, n (%)	1 (3.4)	1 (3.3)	3 (9.7)	5 (5.6)	3 (9.7)	
On treatment but missing data, n (%)	1 (3.4)	0		1 (1.1)	0	





Islatravir: Ongoing trials


- Phase III studies of treatment-naive people (<u>NCT04233879</u>),
- Heavily treatment-experienced people (NCT04233216)
- People with viral suppression who are switching from other regimens (<u>NCT04223778</u> and <u>NCT04223791</u>).
- A phase II study of children and adolescents is also planned (<u>NCT04295772</u>).

Lenacapravir: Background

- Lenacapavir: HIV capsid inhibitor that prevents nuclear assembly, virus assembly and release, and capsid assembly. EC₅₀ 50 picomolar
- Retains full activity against NRTI-, NNTRI-, PI-, and INSTI-resistant HIV-1 in vitro^{3.5}










CAPELLA: Baseline Characteristics


Characteristic	Rand	Randomized		
Median age, yr (range)	55 (24-71)	54 (27-59)	49 (23-78)	52 (23-78)
Female at birth, %	29	25	22	25
Black, %	42	55	31	38
Hispanic/Latinx, %	25	36	14	21
Median HIV-1 RNA, log _{s0} copies/ml (range) • >75,000 copies/mL, %	4.2 (2.3-5.4) 17	4.9 (4.3-5.3) 50	4.5 (1.3-5.7) 28	4.5 (1.3-5.7) 28
Median CD4+ cell count, cells/mm ³ (range) • s200 cells/mm ³ , %	172 (16-827) 67	85 (6-237) 92	195 (3-1296) 53	150 (3-1296) 64
Median time since HIV diagnoses, yr (range)	27 (13-39)	26 (14-35)	23 (9-44)	24 (9-44)
Median prior ARVs, No. (range)	9 (2-24)	9 (3-22)	13 (3-25)	11 (2-25)
Median ARVs in failing regimen, No. (range)	3 (1-7)	3 (2-6)	4 (2-7)	3 (1-7)
Resistance to 22 drugs in class, % NRTI NNRT PI IINSTI	96 92 83 83	100 100 67 58	100 100 83 64	99 97 81 69














CAPELLA: Lenacapravir in MDR HIV


- Lenacapavir, in combination with OBR, demonstrated favorable efficacy and safety at Week 26 in heavily treatment-experienced patients with MDR HIV-1 infection
 - High rate of virologic suppression (81%)
 - Increase in CD4+ cell count (+81 cells/mm³)
 - No patients had CD4+ cell count <50 cells/mm³ at Week 26 vs 22% at baseline
 - Treatment well tolerated with no AEs leading to discontinuation
- All randomized patients received second SC lenacapavir injection
 Data support ongoing evaluation of lenacapavir for
- HIV-1 treatment and prevention in heavily treatment-experienced patients with MDR HIV-1 infection
- More information on resistance needed

Slide adapted from: clinicaloption










CALIBRATE: Adverse Events and Injection Site Reactions




Next Generation Maturation Inhibitor: GSK3640254


GSK'254


- Prevents the proteolytic cleavage of specific portions of the Gag protein which prevents processing of the Gag-Pol polyprotein in late stage of HIV replication.
- Pre-existing mutations at the cleavage site led to termination of development of an earlier maturation inhibibitor (bevirimat).


-Phase 2 A results of a two part study of GSK '254 presented at CROI 2021.




			GSK3640254				Total
	10 mg* (n = 6)	40 mg [*] (n = 6)	80 mg [†] (n = 6)	140 mg [†] (n = 6)	200 mg* (n = 6)	Placebo (n = 4)	(N = 34)
Mean age, yrs (SD)	32.7 (8.3)	27.7 (6.9)	32.8 (6.2)	33.2 (8.2)	29.3 (3.9)	36.5 (9.3)	31.8 (7.2)
Male, n (%)	6 (100)	5 (83)	6 (100)	5 (83)	6 (100)	4 (100)	32 (94)
Mean BMI (SD)	25.3 (3.7)	23.9 (4.3)	24.8 (3.7)	23.4 (1.6)	22.6 (2.2)	23.0 (1.3)	23.9 (3.0)
Race, n (%) • White • Black • Other	2 (33) 0 4 (67)	5 (83) 1 (17) 0	4 (67) 2 (33) 0	5 (83) 1 (17) 0	5 (83) 0 1 (17)	3 (75) 0 1 (25)	24 (71) 4 (12) 6 (18)
Mean HIV-1 RNA, log ₁₀ copies/mL (SD)	4.19 (0.311)	4.67 (0.233)	4.43 (0.510)	4.53 (0.577)	4.82 (0.476)	4.25 (0.417)* 4.25 (0.417) [†]	4.47 (0.489) 4.57 (0.592)








No resistance detected at any dose in part 2 (140 mg, 80 mg, or 40 mg)





GSK'254 Summary


 In ART-naive persons with HIV, novel HIV-1 maturation inhibitor, GSK3640254, demonstrated dose-response activity


- HIV-1 RNA decreased 1.5 \log_{10} copies/mL with 140-mg QD dose and 2.0 \log_{10} copies/mL with 200-mg QD dose

- GSK3640254 was well-tolerated
 - No grade 3/4 AEs and no AEs leading to d/c

Investigators conclude these findings support evaluation of GSK3640254 (100 mg QD, 150 mg QD, and 200 mg QD) in combination with 2 NRTIs in phase IIb study

ner. CROI 2021. Abstr 126





C C C

Future Combinations and Approaches in the works

Long acting cabotegravir and a broadly neutralizing antibodies

 A5357: A single arm trial of long-acting cabotegravir and VRC07LS (a broadly neutralizing antibody; bNAb) as maintenance ART

- A5364: A single arm trial of two bNAbs (3BNC117-LS & 10-1074-LS) to prevent relapse of viremia of discontinuation of oral ART
- A5377, a first-in-human Phase 1 clinical trial of a tri-specific monoclonal antibody (SAR441236) to establish safety, pharmacokinetics, and preliminary antiviral activity
- Ongoing Phase 1 study combined with GS-5423 (AKA 3BNC117-LS) in people with virologic suppression

Investigational Approaches with recently approved agents: Long Acting Cabotegravir and Rilpivirine

- Long acting cabotegravir and rilpivirine approved for use in patients with viral suppression and no prior resistance in an every 4 week dosing schedule in US and Canada. January 21, 2021. (approved for q8 in EU)
- Approved in both an oral formulation cabotegravir 30 mg and rilpivirine and in the sustained release injection to be initiated after an oral lead in.
- ATLAS 2M compared 4 week with 8 week dosing in people who were suppressed on 4 week dosing or suppressed on ART outside the trial
 - Week 96 follow-up (CROI 2021) HIV RNA during q 8 week (91% < 50 copies) non-inferior to q 4 week dosing (90% < 50 copies/ml)
 - Very few grade 3 ISR- rates decreased over time

ACTG 5359

A Phase III Randomized-Control Trial to Evaluate Long-Acting Antiretroviral Therapy in Non-adherent HIV-Infected Individuals

Co-Chairs: Aadia Rana, Jose Castillo-Mancilla Co-Vice Chairs: Raphael J. Landovitz, Karen Tashima Utilless cash incentives to help obtain viral suppression followed by use of long acting Cabotegravir Study Population:

- Study Population:
- ART-experienced, HIV-infected males and non-pregnant females ≥18 years of age with:
 - HIV-1 RNA >200 copies/mL
 Evidence of non-adherence according to at least <u>one</u> of the following criteria:
 - Poor virologic response within 18 months prior to entry in individuals who have been
 prescribed ART for at least 6 consecutive months.
 - Loss to clinical follow-up within 18 months prior to study entry with ART non-adherence for 26 consecutive months.
 - No evidence of any clinically relevant RPV or INSTI resistance-associated mutations (historically or upon screening).
 - Ability of site clinician, in conjunction with participant, to construct a ≥3-drug ART regimen with ≥2 drugs predicted to be fully active, including a boosted PI/cobi and/or an INSTI.

Summary

- New drugs with novel mechanisms of action and less frequent dosing are progressing in development.
 - Islatravir
 - Lenacapravir
 - GSK'254
- Use of approved combination of long acting cabotegravir/rilpivirine
- Slowly being rolled out Investigational approaches with q 8 week dosing, combination with other agents and use in populations that have struggled with adherence in progress.

